)
Melbourne-based respiratory imaging company 4DMedical (ASX: 4DX) has struck a deal with pharmaceutical giant GlaxoSmithKline to supply its proprietary quantitative lung imaging analytics in support of pulmonary drug development and clinical research.
The one-year contract, which kicks off next month and was facilitated in association with imaging data platform Flywheel Exchange, will see 4DMedical's functional lung imaging technology deployed to support GSK's drug development pipeline.
The financial terms of the agreement are commercially confidential, with 4DMedical noting the contract is "not individually material" on a standalone basis.
The deal marks a significant validation of 4DMedical's technology by one of the world's largest pharmaceutical companies and comes four months after the company raised $150 million via an institutional placement to fund its global commercialisation push.
4DMedical founder and CEO Andreas Fouras says the GSK contract demonstrates the growing stature of the company's quantitative imaging analytics in pharmaceutical development.
"As biopharmaceutical companies seek more sensitive, reproducible endpoints to support respiratory drug development, our platform is increasingly well positioned to serve this expanding market alongside our established clinical business," says Fouras.
"Importantly, this engagement also creates the potential to support programs beyond development, including the future use of our technology as a companion diagnostic as therapies progress through to commercialisation."
The company's core CT:VQ technology uses artificial intelligence to convert standard CT lung scans into detailed, quantitative maps of lung ventilation and perfusion, eliminating the need for nuclear medicine scans.
The technology is now deployed at US academic medical centres and holds regulatory clearance across the US, EU, UK, Canada and New Zealand.
4DMedical has secured UKCA certification for CT:VQ in the United Kingdom, extending its regulatory footprint into a major pharmaceutical research market.
"The UK is home to some of the world's most influential cardiopulmonary centres, and our ability to engage directly with these institutions strengthens the global evidence base and clinical credibility of our platform," says Fouras.
The GSK deal was announced today alongside a string of regulatory and commercial milestones.
In the US, 4DMedical secured a new Centers for Medicare & Medicaid Services reimbursement code - G0680 - for AI-enabled coronary calcium analysis at a rate of US$15.50 ($24.18) per study, opening a new revenue stream in cardiac imaging.
The company was also added to the S&P/ASX 200 Index effective 20 April 2026, a milestone that typically broadens a company's investor base by attracting index-tracking funds.
"Collectively, milestones such as pharmaceutical engagement with a global leader, expanding geographic reach, a growing cardiopulmonary portfolio, and inclusion in the ASX 200, reinforce 4DMedical's position as a global platform company in CT-based cardiopulmonary imaging," says Fouras.
"However, what excites me most is what lies ahead. Our commercial pipeline is the deepest and most advanced it has ever been, and I look forward to updating shareholders shortly."
4DMedical was founded by Fouras, who together with CFO Julian Sutton holds approximately 12.4 per cent of the company's shares.
The company has built its technology platform from research originally conducted at Monash University and has progressively expanded from research applications into clinical and pharmaceutical use cases.
)
